122 related articles for article (PubMed ID: 37336688)
1. Hepatocyte NLRP3 interacts with PKCε to drive hepatic insulin resistance and steatosis.
Qin W; Weng J
Sci Bull (Beijing); 2023 Jul; 68(13):1413-1429. PubMed ID: 37336688
[TBL] [Abstract][Full Text] [Related]
2. Hyperhomocysteinemia activates NLRP3 inflammasome to cause hepatic steatosis and insulin resistance via MDM2-mediated ubiquitination of HSF1.
Xiang W; Yang Y; Weng L; Ye Z; Ding P; Li H; Sun J; Zeng C
Int Immunopharmacol; 2023 May; 118():110085. PubMed ID: 37018978
[TBL] [Abstract][Full Text] [Related]
3. Effects of XIAP on high fat diet-induced hepatic steatosis: a mechanism involving NLRP3 inflammasome and oxidative stress.
Zilu S; Qian H; Haibin W; Chenxu G; Deshuai L; Qiang L; Linfeng H; Jun T; Minxuan X
Aging (Albany NY); 2019 Dec; 11(24):12177-12201. PubMed ID: 31841118
[TBL] [Abstract][Full Text] [Related]
4. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
[TBL] [Abstract][Full Text] [Related]
5. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism.
Wan X; Xu C; Lin Y; Lu C; Li D; Sang J; He H; Liu X; Li Y; Yu C
J Hepatol; 2016 Apr; 64(4):925-32. PubMed ID: 26639394
[TBL] [Abstract][Full Text] [Related]
6. Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation.
Sui YH; Luo WJ; Xu QY; Hua J
World J Gastroenterol; 2016 Feb; 22(8):2533-44. PubMed ID: 26937141
[TBL] [Abstract][Full Text] [Related]
7. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
[TBL] [Abstract][Full Text] [Related]
8. Serum amyloid A1 exacerbates hepatic steatosis via TLR4-mediated NF-κB signaling pathway.
Jiang B; Wang D; Hu Y; Li W; Liu F; Zhu X; Li X; Zhang H; Bai H; Yang Q; Yang X; Ben J; Chen Q
Mol Metab; 2022 May; 59():101462. PubMed ID: 35247611
[TBL] [Abstract][Full Text] [Related]
9. Asperuloside alleviates lipid accumulation and inflammation in HFD-induced NAFLD via AMPK signaling pathway and NLRP3 inflammasome.
Shen Q; Chen Y; Shi J; Pei C; Chen S; Huang S; Li W; Shi X; Liang J; Hou S
Eur J Pharmacol; 2023 Mar; 942():175504. PubMed ID: 36641101
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of hepatocyte nuclear factor 1b induces hepatic steatosis through DPP4/NOX1-mediated regulation of superoxide.
Long Z; Cao M; Su S; Wu G; Meng F; Wu H; Liu J; Yu W; Atabai K; Wang X
Free Radic Biol Med; 2017 Dec; 113():71-83. PubMed ID: 28942246
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor binding protein 7 accelerates hepatic steatosis and insulin resistance in non-alcoholic fatty liver disease.
Yan H; Li T; Wang Y; Li H; Xu J; Lu X
Clin Exp Pharmacol Physiol; 2019 Dec; 46(12):1101-1110. PubMed ID: 31397492
[TBL] [Abstract][Full Text] [Related]
12. Hepatic deficiency of selenoprotein S exacerbates hepatic steatosis and insulin resistance.
Qiao L; Men L; Yu S; Yao J; Li Y; Wang M; Yu Y; Wang N; Ran L; Wu Y; Du J
Cell Death Dis; 2022 Mar; 13(3):275. PubMed ID: 35347118
[TBL] [Abstract][Full Text] [Related]
13. FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease.
Liu C; Zhou B; Meng M; Zhao W; Wang D; Yuan Y; Zheng Y; Qiu J; Li Y; Li G; Xiong X; Bian H; Zhang H; Wang H; Ma X; Hu C; Xu L; Lu Y
J Hepatol; 2021 Jul; 75(1):150-162. PubMed ID: 33548387
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitin-Specific Peptidase 10 (USP10) Inhibits Hepatic Steatosis, Insulin Resistance, and Inflammation Through Sirt6.
Luo P; Qin C; Zhu L; Fang C; Zhang Y; Zhang H; Pei F; Tian S; Zhu XY; Gong J; Mao Q; Xiao C; Su Y; Zheng H; Xu T; Lu J; Zhang J
Hepatology; 2018 Nov; 68(5):1786-1803. PubMed ID: 29698567
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease.
Zhang H; Shen Z; Lin Y; Zhang J; Zhang Y; Liu P; Zeng H; Yu M; Chen X; Ning L; Mao X; Cen L; Yu C; Xu C
J Biol Chem; 2020 Mar; 295(12):3891-3905. PubMed ID: 32051143
[TBL] [Abstract][Full Text] [Related]
16. Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance.
Sun N; Shen C; Zhang L; Wu X; Yu Y; Yang X; Yang C; Zhong C; Gao Z; Miao W; Yang Z; Gao W; Hu L; Williams K; Liu C; Chang Y; Gao Y
Gut; 2021 Nov; 70(11):2183-2195. PubMed ID: 33257471
[TBL] [Abstract][Full Text] [Related]
17. GAS5 protects against nonalcoholic fatty liver disease via miR-28a-5p/MARCH7/NLRP3 axis-mediated pyroptosis.
Chen T; Meng Y; Zhou Z; Li H; Wan L; Kang A; Guo W; Ren K; Song X; Chen Y; Zhao W
Cell Death Differ; 2023 Jul; 30(7):1829-1848. PubMed ID: 37337032
[TBL] [Abstract][Full Text] [Related]
18. Ubiquitin-Specific Protease 4 Is an Endogenous Negative Regulator of Metabolic Dysfunctions in Nonalcoholic Fatty Liver Disease in Mice.
Zhao Y; Wang F; Gao L; Xu L; Tong R; Lin N; Su Y; Yan Y; Gao Y; He J; Kong L; Yuan A; Zhuge Y; Pu J
Hepatology; 2018 Sep; 68(3):897-917. PubMed ID: 29573006
[TBL] [Abstract][Full Text] [Related]
19. Hepatic Zbtb18 (Zinc Finger and BTB Domain Containing 18) alleviates hepatic steatohepatitis via FXR (Farnesoid X Receptor).
Zhang L; Chen J; Yang X; Shen C; Huang J; Zhang D; Liu N; Liu C; Zhong Y; Chen Y; Tang K; Guo J; Cui T; Duan S; Li J; Huang S; Pan H; Zhang H; Tang X; Chang Y; Gao Y
Signal Transduct Target Ther; 2024 Jan; 9(1):20. PubMed ID: 38263084
[TBL] [Abstract][Full Text] [Related]
20. Targeting DUSP7 signaling alleviates hepatic steatosis, inflammation and oxidative stress in high fat diet (HFD)-fed mice via suppression of TAK1.
Wu L; Liu Y; Zhao Y; Li M; Guo L
Free Radic Biol Med; 2020 Jun; 153():140-158. PubMed ID: 32311490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
